Labcorp's modern form dates to 1995, when Roche Biomedical Laboratories and National Health Laboratories merged to create Laboratory Corporation of America Holdings. National Health Laboratories had been founded in the 1970s by James Powell and grew through acquisitions of independent clinical laboratories. Roche Biomedical was the US clinical laboratory subsidiary of Swiss pharmaceutical giant Roche. The merger combined National Health's operational scale with Roche's scientific capabilities and international presence, creating the second-largest independent clinical laboratory company in the United States. In the late 1990s and early 2000s, Labcorp expanded through organic growth and acquisitions, building a national network of patient service centers and primary laboratories. The company invested in automation and information technology to reduce processing costs and improve turnaround times, establishing the operational infrastructure that would support future scale. A transformative moment came in 2015 when Labcorp acquired Covance Inc. for approximately $6.1 billion in cash and stock. Covance was a leading contract research organization providing drug development and commercialization services to pharmaceutical and biotechnology companies. The acquisition was transformative, creating a combined company with pro forma revenue of $8.4 billion and positioning Labcorp as a leader in both diagnostics and drug development services. Covance shareholders received $75.76 in cash and 0.2686 Labcorp shares per share, representing a 32% premium. The deal was expected to generate annual cost synergies exceeding $100 million within three years. Following the Covance acquisition, Labcorp pursued additional specialty testing capabilities. The 2016 acquisition of Sequenom strengthened prenatal and genetic testing capabilities. The 2022 acquisition of Personal Genome Diagnostics added precision oncology and genomic capabilities. These acquisitions expanded Labcorp's test menu beyond routine chemistry and hematology into higher-margin, higher-complexity testing categories. In 2023, Labcorp spun off its clinical development and commercialization services business as Fortrea Holdings Inc., creating a more focused diagnostics and laboratory services company. The spin-off reversed the diversification strategy that had driven the Covance acquisition, reflecting management's view that diagnostics and clinical development were distinct businesses with different capital requirements, growth profiles, and competitive dynamics. Fortrea began trading as an independent public company in 2023. In 2024, Labcorp changed its legal name to Labcorp Holdings Inc., reflecting the company's operating brand and simplified corporate structure post-spin-off. The company continued its acquisition strategy with the purchase of select Invitae assets (advancing specialty testing in oncology and rare diseases) and BioReference Health's diagnostic business (expanding clinical diagnostics and reproductive health capabilities).